Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-interleukin-8 monoclonal antibody

Next Previous
Drug Profile

Anti-interleukin-8 monoclonal antibody

Alternative Names: ABX-IL8; Anti-IL-8 antibody

Latest Information Update: 05 Apr 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XenoTech LLC
  • Developer Abgenix; XenoTech
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Inflammation; Inflammatory bowel diseases; Malignant melanoma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 02 Dec 2004 A study has been added to the adverse events and Respiratory Tract Disorders therapeutic trials sections
  • 22 Mar 2004 ABX-IL8 is available for licensing in the indication of chronic obstructive pulmonary disease (http://www.abgenix.com)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top